Phase I-IV Clinical Trials

 

  • over 200 Phase II and III studies completed
  • 35-40 new studies initiated/year
  • more than 1500 subjects randomized in the last 3 years
  • 3 regulatory inspection by Hungarian Regulatory Authority (2009, 2015, 2018)
  • 2 FDA inspection with NAI (No Action Indicated) results in 2017 and 2018
  • over 30 sponsor and CRO audits successfully completed
  • currently worldwide top enroller in many studies in different indications
  • patient retention is over 95%
  • contracted recruitment targets reached 99% of the cases
  • Therapeutic areas: pulmonology, onco-pulmonology, cardiology, diabetology, lipidology, rheumatology, gastroenterology, infectology, gynecology, dermatology, neurology, psychiatry.